| HOME >> BIOLOGY >> TECHNOLOGY |
Operating income. Operating income was RMB27.9 million (US$4.1 million) for the second quarter of 2010, an increase of 8.2% from operating income of RMB25.8 million (US$3.8 million) for the same period in 2009. Operating margin for the second quarter of 2010 was 26.5% as compared to 31.7% for the same period in 2009.
Interest income. The Company recorded net interest income of RMB2.4 million (US$0.3 million) for the second quarter of 2010, compared to RMB2.5 million (US$0.4 million) for the same period in 2009.
Net income. GAAP net income was RMB25.5 million (US$3.8 million) for the second quarter of 2010, 5.4% lower than net income of RMB27.0 million (US$0.4 million) for the same period in 2009. GAAP net income per ADS on a fully- diluted basis for the second quarter of 2010 increased to RMB1.16 (US$0.17) from RMB1.25 (US$0.18) for the same period in 2009. GAAP net margin for the second quarter of 2010 was 24.2% as compared to 33.1% for the same period in 2009.
Non-GAAP net income for the second quarter of 2010 was RMB25.5 million (US$3.8 million), 0.6% higher than non-GAAP net income of RMB25.4 million (US$3.7 million) for the same period in 2009.
Non-GAAP net income per ADS on a fully-diluted basis for the second quarter of 2010 decreased to RMB1.16 (US$0.17) from RMB1.18 (US$0.17) for the same period in 2009. Non-GAAP net margin for the second quarter of 2010 was 24.2% as compared to 31.1% for the same period in 2009.
Six months ended June 30, 2010 Unaudited Financial Results
Net revenues. Net revenues for the first half of 2010 increased by 34.5%
to RMB201.9 million (US$29.8 million), from RMB150.1 million (US$22.0 million)
for the same period in 2009. The increase was primarily attributable to
increased sales from our EPIAO and TPIAO products, underpinned by continued
strong demand in the oncology and nephrology marke
'/>"/>
| SOURCE 3SBio Inc. Copyright©2010 PR Newswire. All rights reserved |